OncoMatch/Blood Cancer — Myelodysplastic (MDS)/SF3B1
Blood Cancer — Myelodysplastic (MDS)SF3B1 Clinical Trials
SF3B1 mutations occur in approximately 25–30% of MDS, are strongly associated with the ring sideroblast morphology, and define a relatively favorable-risk subgroup. Luspatercept, an erythroid maturation agent, is FDA-approved for SF3B1-mutant MDS with ring sideroblasts. Trials investigate luspatercept combinations, novel splicing modulators, and early-intervention strategies in SF3B1-mutant low-risk MDS.
Top recruiting SF3B1 Blood Cancer — Myelodysplastic (MDS) trials
Ranked by phase and US site count.
See all trials matched to your profile →Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
Luspatercept + Darbepoetin in MDS
Yale University
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Uma Borate